The Therapeutic Alliance's Moderating Role on the Negative Relationship Between Dread of Ego Dissolution and Changes in Depression Symptom Severity in Psilocybin-Assisted Therapy for Treatment-Resistant Depression: A Secondary Analysis of the PsiDeR Trial.
Canyon Akromis, Lorraine Li, Kwon Mok Ko, Petrina Chu, Tim Mantingh, James Rucker
Study at a glance
AI-extracted from the abstract| Characteristics | Secondary analysis of a phase II randomized placebo-controlled trial |
|---|---|
| Population | Participants with treatment-resistant depression |
| Interventions | Psilocybin placebo psychotherapy |
| Dose | 25 mg |
| Measures | Scale to Assess the Therapeutic Relationship-Patient/Clinician (STAR-P/C), 5-Dimension Altered State of Consciousness dread of ego dissolution subscale (5D-ASC-DED), Montgomery–Åsberg Depression Rating Scale (MADRS) |
| Topics | Depression Ego dissolution Psilocybin |
| Key findings | The analysis tests whether therapeutic alliance moderates the relationship between dread of ego dissolution and depression symptom severity in people with treatment-resistant depression who received psilocybin or placebo with psychotherapy. No results are reported in the abstract. |
Abstract
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the Scale to Assess the Therapeutic Relationship-Patient/Clinician (STAR-P/C), moderates the relationship between the dread of ego dissolution subscale of the 5-Dimension Altered State of Consciousness (5D-ASC-DED) and treatment-related outcomes of depression symptom severity, measured by Montgomery–Åsberg Depression Rating Scale (MADRS).
Comparable studies
Other randomized controlled trials on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
| Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Adults with treatment-resistant depression | 2022 | Phase 2 double-blind randomized controlled trial | n = 233 |